Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Forte Biosciences, Inc.TOCA · Entity 9529 | Director · Chief Executive Officer | October 04, 2019 | October 05, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Forte Biosciences, Inc.
Report date October 04, 2019 · Filed October 05, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.64 · Expires 2029-10-03 | Direct | 50,000 |
Reported balance
After 2019-10-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-10-04 · Grant · Acquired 50,000 · Balance 50,000 F1: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 04, 2019 Filed Oct 5, 2019 00:34 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001209191-19-052620 · doc4.xml · derivative · entry 1 Duvall Martin J · CIK 0001313390 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-10-03 F1 · derivative.exercise_date: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. Read SEC document |
| May 28, 2019 Filed May 29, 2019 20:25 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | PurchaseCommon Stock | 5,000 | $4.34 | $21,678.50 |
DisclosureSEC source: 0001209191-19-033190 · doc4.xml · nonDerivative · entry 1 Duvall Martin J · CIK 0001313390 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,605 F1 · balance_after: Includes 1,566 shares of Common Stock that were acquired by the Reporting Person on June 8, 2018 pursuant to the Issuer's Employee Stock Purchase Plan and 968 shares of Common Stock that were acquired by the Reporting Person on December 10, 2018 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:06 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantEmployee Stock Option (right to buy) · Derivative | 160,000 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016896 · doc4.xml · derivative · entry 1 Duvall Martin J · CIK 0001313390 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2029-02-28 F1 · derivative.exercise_date: 25% of the shares vest on 3/1/2020 amd the balance of the shares vest monthly thereafter. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 22:15 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $11.19 | $0.00 |
DisclosureSEC source: 0001209191-18-015824 · doc4.xml · derivative · entry 1 Duvall Martin J · CIK 0001313390 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-02-29 F1 · derivative.exercise_date: 1/4th of the shares vest one year after 3/01/2018; the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of 3/01/2018. Read SEC document |
| December 08, 2017 Filed Dec 15, 2017 02:02 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | OtherCommon Stock | 2,500 | $8.50 | $21,250.00 |
DisclosureSEC source: 0001209191-17-065788 · doc4.xml · nonDerivative · entry 1 Duvall Martin J · CIK 0001313390 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,071 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 2,500 shares by the Reporting Person on December 8, 2017 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| May 26, 2017 Filed Jun 1, 2017 00:34 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantEmployee Stock Option (right to buy) · Derivative | 285,000 | $0.00 Strike: $16.32 | $0.00 |
DisclosureSEC source: 0001209191-17-036617 · doc4.xml · derivative · entry 1 Duvall Martin J · CIK 0001313390 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,000 Underlying: Common Stock · 285,000 shares Expires 2027-05-25 F1 · derivative.exercise_date: 1/4th of the shares vest one year after 5/26/2017; the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of 5/26/2017. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 21:39 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | OtherCommon Stock | 3,571 | $10.00 | $35,710.00 |
DisclosureSEC source: 0001209191-17-027908 · doc4.xml · nonDerivative · entry 1 Duvall Martin J · CIK 0001313390 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,571 F1 · kind: Represents the conversion of outstanding convertible promissory notes in the aggregate principal amount of $35,000, plus an aggregate of $714.39 accrued interest, into shares of the Issuer's common stock upon closing of the Issuer's initial public offering at a conversion price of $10.00 per share. Read SEC document |
| April 12, 2017 Filed Apr 13, 2017 00:59 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantEmployee Stock Option (right to buy) · Derivative | 46,739 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001209191-17-026750 · doc4.xml · derivative · entry 1 Duvall Martin J · CIK 0001313390 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,739 Underlying: Common Stock · 46,739 shares Expires 2027-04-11 F1 · derivative.exercise_date: 1/4th of the shares vest one year after 4/1/2017; the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of 4/1/2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.